These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17283252)

  • 21. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
    Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
    Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats.
    González GE; Rhaleb NE; Nakagawa P; Liao TD; Liu Y; Leung P; Dai X; Yang XP; Carretero OA
    Clin Sci (Lond); 2014 Jan; 126(1):85-94. PubMed ID: 23834332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
    Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
    J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M; Junot C; Ezan E; Ménard J
    Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice.
    Chan GC; Yiu WH; Wu HJ; Wong DW; Lin M; Huang XR; Lan HY; Tang SC
    Mediators Inflamm; 2015; 2015():283123. PubMed ID: 26508815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
    J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction.
    Yang F; Yang XP; Liu YH; Xu J; Cingolani O; Rhaleb NE; Carretero OA
    Hypertension; 2004 Feb; 43(2):229-36. PubMed ID: 14691195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal Protective Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) in Obese Rats on a High-Salt Diet.
    Maheshwari M; Romero CA; Monu SR; Kumar N; Liao TD; Peterson EL; Carretero OA
    Am J Hypertens; 2018 Jul; 31(8):902-909. PubMed ID: 29722788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
    Romero CA; Kumar N; Nakagawa P; Worou ME; Liao TD; Peterson EL; Carretero OA
    Am J Physiol Renal Physiol; 2019 Jan; 316(1):F195-F203. PubMed ID: 30403163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
    Hrenak J; Paulis L; Simko F
    Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
    Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
    Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats.
    Cingolani OH; Yang XP; Liu YH; Villanueva M; Rhaleb NE; Carretero OA
    Hypertension; 2004 May; 43(5):1067-73. PubMed ID: 15023934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.
    Kanasaki M; Nagai T; Kitada M; Koya D; Kanasaki K
    Fibrogenesis Tissue Repair; 2011 Nov; 4():25. PubMed ID: 22126210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y
    J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy.
    Tang SC; Leung JC; Chan LY; Eddy AA; Lai KN
    Kidney Int; 2008 Feb; 73(3):288-99. PubMed ID: 18033243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.
    Kumar N; Nakagawa P; Janic B; Romero CA; Worou ME; Monu SR; Peterson EL; Shaw J; Valeriote F; Ongeri EM; Niyitegeka JM; Rhaleb NE; Carretero OA
    Am J Physiol Renal Physiol; 2016 May; 310(10):F1026-34. PubMed ID: 26962108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
    Kwakernaak AJ; Waanders F; Slagman MC; Dokter MM; Laverman GD; de Boer RA; Navis G
    J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.
    van der Meer P; Lipsic E; Westenbrink BD; van de Wal RM; Schoemaker RG; Vellenga E; van Veldhuisen DJ; Voors AA; van Gilst WH
    Circulation; 2005 Sep; 112(12):1743-7. PubMed ID: 16172283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus.
    Liao TD; Nakagawa P; Janic B; D'Ambrosio M; Worou ME; Peterson EL; Rhaleb NE; Yang XP; Carretero OA
    Am J Physiol Renal Physiol; 2015 May; 308(10):F1146-54. PubMed ID: 25740596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
    Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
    Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.